Pacira Biosciences, INC Form 4 insider transactions

Pacira BioSciences' Chief Commercial Officer, Brendan Teehan, acquired 402.268 shares of common stock through an employee stock purchase plan.

Pacira BioSciences' Chief Financial Officer, Shawn Cross, executed pre-planned sales of common stock totaling 25,000 shares after exercising stock options.

Pacira BioSciences' Chief Medical Officer, Jonathan Slonin, sold 3,960 shares of common stock for $24.09 per share under a pre-arranged 10b5-1 trading plan.

Pacira BioSciences' Chief Financial Officer, Shawn Cross, sold 12,060 shares of common stock at $22.09 per share as part of a pre-established Rule 10b5-1 trading plan.

Pacira BioSciences' Chief Financial Officer, Shawn Cross, disposed of 6,690 shares of common stock to cover tax obligations upon the vesting of restricted stock units.

Pacira BioSciences Director Abraham Ceesay has scheduled the sale of 2,354 shares of common stock for September 4, 2025, at a price of $27.19 per share, under a pre-arranged 10b5-1 trading plan.

Pacira BioSciences Director Marcelo Bigal reported the sale of 4,912 shares of common stock at $23.67 per share.

Pacira BioSciences' Chief Medical Officer, Jonathan Slonin, reported changes in his beneficial ownership, including shares withheld for taxes and shares acquired via an employee stock purchase plan.

Pacira BioSciences, Inc. Director Mark A. Kronenfeld was granted 9,999 restricted stock units and options to purchase 11,279 shares of common stock as part of his compensation.

Pacira BioSciences, Inc. Director Abraham Ceesay was granted 6,163 restricted stock units and options to purchase 11,279 shares of common stock, aligning his interests with shareholders.

Pacira BioSciences, Inc. Director Mark Froimson reported the acquisition of 6,163 restricted stock units and 11,279 stock options on June 11, 2025, as part of his compensation.

Pacira BioSciences, Inc. Director Marcelo Bigal was granted 6,163 restricted stock units and 11,279 stock options as part of his compensation, aligning his interests with shareholders.

Pacira BioSciences, Inc. Director Michael J. Yang has reported the acquisition of 6,163 restricted stock units and 11,279 stock options as part of a compensation grant on June 11, 2025.

Pacira BioSciences, Inc. Director Christopher Christie reported the acquisition of 6,163 restricted stock units and 11,279 stock options on June 11, 2025, as part of his compensation.

Pacira BioSciences, Inc. Director Alethia Young was granted 6,163 restricted stock units and options to purchase 11,279 shares of common stock on June 11, 2025, as part of her compensation.

Pacira BioSciences, Inc. director Laura Brege was granted 6,163 restricted stock units and 11,279 stock options, aligning her interests with shareholders.

Lauren Riker, Senior Vice President of Finance at Pacira BioSciences, Inc., reported the sale of common stock totaling 5,578.335 shares after a portion was withheld for tax obligations related to a restricted stock unit award.

Pacira BioSciences' Chief Administrative Officer, Kristen Williams, reported the sale of 14,376 shares of common stock and the withholding of 6,162 shares for tax obligations, reducing her beneficial ownership to 161,574 shares.

Jonathan Slonin, Chief Medical Officer of Pacira BioSciences, Inc., reported the disposition of 5,084 shares of common stock to cover tax obligations related to a restricted stock unit award vesting.

Jonathan Slonin, Chief Medical Officer of Pacira BioSciences, reports the acquisition of restricted stock units that vest over four years.

Kristen Williams, Chief Administrative Officer of Pacira BioSciences, reports the acquisition of 79,200 restricted stock units.

Frank D. Lee, CEO of Pacira BioSciences, acquired 350,000 shares of common stock on February 1, 2025, as part of a restricted stock unit grant.

Brendan Teehan, Chief Commercial Officer of Pacira BioSciences, reports acquisition of common stock and stock options.

Lauren Riker, Senior Vice President of Finance at Pacira BioSciences, reports the acquisition of restricted stock units that vest annually starting February 1, 2026.

Pacira BioSciences CEO, Frank D. Lee, sold 9,375 shares of common stock to cover tax obligations related to vesting restricted stock units.

Pacira BioSciences' Chief Medical Officer, Jonathan Slonin, sold shares to cover tax obligations and under a pre-arranged trading plan.

The Chief Operating Officer of Pacira BioSciences, Inc. has increased their holdings in the company by acquiring additional shares through the employee stock purchase plan.

A Pacira BioSciences executive, Lauren Riker, sold 159 shares of common stock to cover tax obligations related to vesting restricted stock units.

Pacira BioSciences' Chief Operating Officer, Daryl Gaugler, sold 500 shares of common stock at $19.76 per share on December 13, 2024, under a pre-arranged 10b5-1 trading plan.

Pacira BioSciences' CFO, Shawn Cross, reports the acquisition of stock options and restricted stock units, indicating changes in beneficial ownership.